Selected research
Industry Research
Nuclear Receptor ROR-Gamma Industry Research Report 2026
Market perspective
The global Nuclear Receptor ROR-Gamma market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nuclear Receptor ROR-Gamma market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nuclear Receptor ROR-Gamma market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nuclear Receptor ROR-Gamma market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nuclear Receptor ROR-Gamma include 4SC AG, Vitae Pharmaceuticals, Inc., Visionary Pharmaceuticals, Inc., Teijin Pharma Limited, Reata Pharmaceuticals, Inc., Phenex Pharmaceuticals AG, Nuevolution AB, Lead Pharma Holding B.V. and Karo Bio AB, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nuclear Receptor ROR-Gamma market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nuclear Receptor ROR-Gamma.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nuclear Receptor ROR-Gamma Market by Company
4SC AG
Vitae Pharmaceuticals, Inc.
Visionary Pharmaceuticals, Inc.
Teijin Pharma Limited
Reata Pharmaceuticals, Inc.
Phenex Pharmaceuticals AG
Nuevolution AB
Lead Pharma Holding B.V.
Karo Bio AB
Hanmi Pharmaceuticals, Co. Ltd.
GlaxoSmithKline Plc
Genfit SA
Genentech, Inc.
Celgene Corporation
Bristol-Myers Squibb Company
Brickell Biotech, Inc.
Biogen, Inc.
Aurigene Discovery Technologies Limited
Arrien Pharmaceuticals, LLC
Advinus Therapeutics Ltd.
Nuclear Receptor ROR-Gamma Segment by Type
BBI-6000
GSK-2981278
INV-17
VPR-66
Others
Nuclear Receptor ROR-Gamma Segment by Application
Hospital
Clinic
Others
Nuclear Receptor ROR-Gamma Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Receptor ROR-Gamma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Receptor ROR-Gamma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Receptor ROR-Gamma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nuclear Receptor ROR-Gamma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- BBI-6000
- GSK-2981278
- INV-17
- VPR-66
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- 4SC AG
- Vitae Pharmaceuticals, Inc.
- Visionary Pharmaceuticals, Inc.
- Teijin Pharma Limited
- Reata Pharmaceuticals, Inc.
- Phenex Pharmaceuticals AG
- Nuevolution AB
- Lead Pharma Holding B.V.
- Karo Bio AB
- Hanmi Pharmaceuticals, Co. Ltd.
- GlaxoSmithKline Plc
- Genfit SA
- Genentech, Inc.
- Celgene Corporation
- Bristol-Myers Squibb Company
- Brickell Biotech, Inc.
- Biogen, Inc.
- Aurigene Discovery Technologies Limited
- Arrien Pharmaceuticals, LLC
- Advinus Therapeutics Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nuclear Receptor ROR-Gamma by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 BBI-6000
- 2.2.3 GSK-2981278
- 2.2.4 INV-17
- 2.2.5 VPR-66
- 2.2.6 Others
- 2.3 Nuclear Receptor ROR-Gamma by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Nuclear Receptor ROR-Gamma Breakdown Data by Type
- 3.1 Global Nuclear Receptor ROR-Gamma Historic Market Size by Type (2021-2026)
- 3.2 Global Nuclear Receptor ROR-Gamma Forecasted Market Size by Type (2027-2032)
4 Nuclear Receptor ROR-Gamma Breakdown Data by Application
- 4.1 Global Nuclear Receptor ROR-Gamma Historic Market Size by Application (2021-2026)
- 4.2 Global Nuclear Receptor ROR-Gamma Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nuclear Receptor ROR-Gamma Market Perspective (2021-2032)
- 5.2 Global Nuclear Receptor ROR-Gamma Growth Trends by Region
- 5.2.1 Global Nuclear Receptor ROR-Gamma Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nuclear Receptor ROR-Gamma Historic Market Size by Region (2021-2026)
- 5.2.3 Nuclear Receptor ROR-Gamma Forecasted Market Size by Region (2027-2032)
- 5.3 Nuclear Receptor ROR-Gamma Market Dynamics
- 5.3.1 Nuclear Receptor ROR-Gamma Industry Trends
- 5.3.2 Nuclear Receptor ROR-Gamma Market Drivers
- 5.3.3 Nuclear Receptor ROR-Gamma Market Challenges
- 5.3.4 Nuclear Receptor ROR-Gamma Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nuclear Receptor ROR-Gamma Players by Revenue
- 6.1.1 Global Top Nuclear Receptor ROR-Gamma Players by Revenue (2021-2026)
- 6.1.2 Global Nuclear Receptor ROR-Gamma Revenue Market Share by Players (2021-2026)
- 6.2 Global Nuclear Receptor ROR-Gamma Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nuclear Receptor ROR-Gamma Head Office and Area Served
- 6.4 Global Nuclear Receptor ROR-Gamma Players, Product Type & Application
- 6.5 Global Nuclear Receptor ROR-Gamma Manufacturers Established Date
- 6.6 Global Nuclear Receptor ROR-Gamma Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nuclear Receptor ROR-Gamma Market Size (2021-2032)
- 7.2 North America Nuclear Receptor ROR-Gamma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nuclear Receptor ROR-Gamma Market Size by Country (2021-2026)
- 7.4 North America Nuclear Receptor ROR-Gamma Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nuclear Receptor ROR-Gamma Market Size (2021-2032)
- 8.2 Europe Nuclear Receptor ROR-Gamma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nuclear Receptor ROR-Gamma Market Size by Country (2021-2026)
- 8.4 Europe Nuclear Receptor ROR-Gamma Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nuclear Receptor ROR-Gamma Market Size (2021-2032)
- 9.2 Asia-Pacific Nuclear Receptor ROR-Gamma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nuclear Receptor ROR-Gamma Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nuclear Receptor ROR-Gamma Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nuclear Receptor ROR-Gamma Market Size (2021-2032)
- 10.2 South America Nuclear Receptor ROR-Gamma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nuclear Receptor ROR-Gamma Market Size by Country (2021-2026)
- 10.4 South America Nuclear Receptor ROR-Gamma Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nuclear Receptor ROR-Gamma Market Size (2021-2032)
- 11.2 Middle East & Africa Nuclear Receptor ROR-Gamma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nuclear Receptor ROR-Gamma Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nuclear Receptor ROR-Gamma Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 4SC AG
- 12.1.1 4SC AG Company Information
- 12.1.2 4SC AG Business Overview
- 12.1.3 4SC AG Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.1.4 4SC AG Nuclear Receptor ROR-Gamma Product Portfolio
- 12.1.5 4SC AG Recent Developments
- 12.2 Vitae Pharmaceuticals, Inc.
- 12.2.1 Vitae Pharmaceuticals, Inc. Company Information
- 12.2.2 Vitae Pharmaceuticals, Inc. Business Overview
- 12.2.3 Vitae Pharmaceuticals, Inc. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.2.4 Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.2.5 Vitae Pharmaceuticals, Inc. Recent Developments
- 12.3 Visionary Pharmaceuticals, Inc.
- 12.3.1 Visionary Pharmaceuticals, Inc. Company Information
- 12.3.2 Visionary Pharmaceuticals, Inc. Business Overview
- 12.3.3 Visionary Pharmaceuticals, Inc. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.3.4 Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.3.5 Visionary Pharmaceuticals, Inc. Recent Developments
- 12.4 Teijin Pharma Limited
- 12.4.1 Teijin Pharma Limited Company Information
- 12.4.2 Teijin Pharma Limited Business Overview
- 12.4.3 Teijin Pharma Limited Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.4.4 Teijin Pharma Limited Nuclear Receptor ROR-Gamma Product Portfolio
- 12.4.5 Teijin Pharma Limited Recent Developments
- 12.5 Reata Pharmaceuticals, Inc.
- 12.5.1 Reata Pharmaceuticals, Inc. Company Information
- 12.5.2 Reata Pharmaceuticals, Inc. Business Overview
- 12.5.3 Reata Pharmaceuticals, Inc. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.5.4 Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.5.5 Reata Pharmaceuticals, Inc. Recent Developments
- 12.6 Phenex Pharmaceuticals AG
- 12.6.1 Phenex Pharmaceuticals AG Company Information
- 12.6.2 Phenex Pharmaceuticals AG Business Overview
- 12.6.3 Phenex Pharmaceuticals AG Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.6.4 Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Product Portfolio
- 12.6.5 Phenex Pharmaceuticals AG Recent Developments
- 12.7 Nuevolution AB
- 12.7.1 Nuevolution AB Company Information
- 12.7.2 Nuevolution AB Business Overview
- 12.7.3 Nuevolution AB Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.7.4 Nuevolution AB Nuclear Receptor ROR-Gamma Product Portfolio
- 12.7.5 Nuevolution AB Recent Developments
- 12.8 Lead Pharma Holding B.V.
- 12.8.1 Lead Pharma Holding B.V. Company Information
- 12.8.2 Lead Pharma Holding B.V. Business Overview
- 12.8.3 Lead Pharma Holding B.V. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.8.4 Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.8.5 Lead Pharma Holding B.V. Recent Developments
- 12.9 Karo Bio AB
- 12.9.1 Karo Bio AB Company Information
- 12.9.2 Karo Bio AB Business Overview
- 12.9.3 Karo Bio AB Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.9.4 Karo Bio AB Nuclear Receptor ROR-Gamma Product Portfolio
- 12.9.5 Karo Bio AB Recent Developments
- 12.10 Hanmi Pharmaceuticals, Co. Ltd.
- 12.10.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
- 12.10.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
- 12.10.3 Hanmi Pharmaceuticals, Co. Ltd. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.10.4 Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.10.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
- 12.11 GlaxoSmithKline Plc
- 12.11.1 GlaxoSmithKline Plc Company Information
- 12.11.2 GlaxoSmithKline Plc Business Overview
- 12.11.3 GlaxoSmithKline Plc Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.11.4 GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Product Portfolio
- 12.11.5 GlaxoSmithKline Plc Recent Developments
- 12.12 Genfit SA
- 12.12.1 Genfit SA Company Information
- 12.12.2 Genfit SA Business Overview
- 12.12.3 Genfit SA Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.12.4 Genfit SA Nuclear Receptor ROR-Gamma Product Portfolio
- 12.12.5 Genfit SA Recent Developments
- 12.13 Genentech, Inc.
- 12.13.1 Genentech, Inc. Company Information
- 12.13.2 Genentech, Inc. Business Overview
- 12.13.3 Genentech, Inc. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.13.4 Genentech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.13.5 Genentech, Inc. Recent Developments
- 12.14 Celgene Corporation
- 12.14.1 Celgene Corporation Company Information
- 12.14.2 Celgene Corporation Business Overview
- 12.14.3 Celgene Corporation Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.14.4 Celgene Corporation Nuclear Receptor ROR-Gamma Product Portfolio
- 12.14.5 Celgene Corporation Recent Developments
- 12.15 Bristol-Myers Squibb Company
- 12.15.1 Bristol-Myers Squibb Company Company Information
- 12.15.2 Bristol-Myers Squibb Company Business Overview
- 12.15.3 Bristol-Myers Squibb Company Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.15.4 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Product Portfolio
- 12.15.5 Bristol-Myers Squibb Company Recent Developments
- 12.16 Brickell Biotech, Inc.
- 12.16.1 Brickell Biotech, Inc. Company Information
- 12.16.2 Brickell Biotech, Inc. Business Overview
- 12.16.3 Brickell Biotech, Inc. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.16.4 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.16.5 Brickell Biotech, Inc. Recent Developments
- 12.17 Biogen, Inc.
- 12.17.1 Biogen, Inc. Company Information
- 12.17.2 Biogen, Inc. Business Overview
- 12.17.3 Biogen, Inc. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.17.4 Biogen, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.17.5 Biogen, Inc. Recent Developments
- 12.18 Aurigene Discovery Technologies Limited
- 12.18.1 Aurigene Discovery Technologies Limited Company Information
- 12.18.2 Aurigene Discovery Technologies Limited Business Overview
- 12.18.3 Aurigene Discovery Technologies Limited Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.18.4 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Product Portfolio
- 12.18.5 Aurigene Discovery Technologies Limited Recent Developments
- 12.19 Arrien Pharmaceuticals, LLC
- 12.19.1 Arrien Pharmaceuticals, LLC Company Information
- 12.19.2 Arrien Pharmaceuticals, LLC Business Overview
- 12.19.3 Arrien Pharmaceuticals, LLC Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.19.4 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Product Portfolio
- 12.19.5 Arrien Pharmaceuticals, LLC Recent Developments
- 12.20 Advinus Therapeutics Ltd.
- 12.20.1 Advinus Therapeutics Ltd. Company Information
- 12.20.2 Advinus Therapeutics Ltd. Business Overview
- 12.20.3 Advinus Therapeutics Ltd. Revenue in Nuclear Receptor ROR-Gamma Business (2021-2026)
- 12.20.4 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Product Portfolio
- 12.20.5 Advinus Therapeutics Ltd. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst